Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1342 participants.
Also called NCT01237223
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,342 participants
- Sponsor
- Registry
-
NCT01237223
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01237223. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2012-06-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Aliskiren/Amlodipine 150/2.5 mg
- Intervention (Drug)
- Aliskiren/amlodipine 150/5 mg
- Intervention (Drug)
- Aliskiren 150 mg
- Intervention (Drug)
- Amlodipine 2.5 mg
- Intervention (Drug)
- Placebo of Aliskiren
- Intervention (Drug)
- Placebo of Amlodipine
- Intervention (Drug)
- Placebo of Aliskiren/amlodipine 150/2.5 mg
- Intervention (Drug)
- Placebo of Aliskiren/amlodipine 150/5 mg
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01237223- Content hash
950c87463c0004a8c8cd079092b796873d9f220d28ab87234cf0688633fc1647